oru.sePublikationer
Change search
ReferencesLink to record
Permanent link

Direct link
Clinical implications of assay specific differences in f-calprotectin when monitoring inflammatory bowel disease activity over time
Örebro University, School of Medical Sciences.
Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Department of Medical Sciences, Gastroenterology Research Group, Uppsala University, Uppsala, Sweden.
Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Örebro, Sweden.
Show others and affiliations
2016 (English)In: Scandinavian Journal of Gastroenterology, ISSN 0036-5521, E-ISSN 1502-7708Article in journal (Refereed) Epub ahead of print
Abstract [en]

Objective: With several faecal calprotectin (FC) assays on the market, it has been difficult to define a uniform threshold for discriminating between remission and active disease in patients with inflammatory bowel disease (IBD). We aimed to compare the results of different FC-assays in IBD patients, followed over time.

Material and methods: IBD patients provided faecal samples and reported clinical activity every third month prospectively over a two year period. FC was measured with two ELISA - (Bühlmann and Immunodiagnostik) and one automated fluoroimmunoassay (Phadia).

Results: In total, 13 patients provided 91 faecal samples. The median (IQR) concentration of FC was higher at active disease than at remission for all assays: Bühlmann 845 (1061-226) μg/g versus 62 (224-39) μg/g, Phadia 369 (975-122) μg/g versus 11 (52-11) μg/g, and Immundiagnostik 135 (302-69) μg/g versus 8 (56-4) μg/g. The Bühlmann assay produced the largest absolute difference but the corresponding relative difference seemed to be more pronounced when analysed by the Phadia - (ratio of means 8.5; 95% CI 3.3-21.9) or the Immundiagnostik assay (ratio of means 7.4; 95% CI 3.1-17.6) than by the Bühlmann assay (ratio of means 5.3; 95% CI 2.7-10.6). Consequently, the specificity for discriminating active disease from remission varied between assays (34-75%) when the cut-off 50 μg/g was used, whereas the differences in sensitivity were less pronounced.

Conclusions: Cross-comparisons revealed overall poor agreement between the assays as well as differences in the dynamics of FC. These findings suggest that standardisation of the method is needed to implement FC as a disease monitoring tool at large-scale.

Place, publisher, year, edition, pages
Oxfordshire, United Kingdom: Taylor & Francis, 2016.
Keyword [en]
Biomarker; Crohn's disease, faecal calprotectin, inflammatory bowel, disease, ulcerative colitis
National Category
Gastroenterology and Hepatology
Identifiers
URN: urn:nbn:se:oru:diva-53665DOI: 10.1080/00365521.2016.1256424PubMedID: 27881032OAI: oai:DiVA.org:oru-53665DiVA: diva2:1050117
Available from: 2016-11-28 Created: 2016-11-28 Last updated: 2016-11-28Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Amcoff, KarinHalfvarson, Jonas
By organisation
School of Medical Sciences
In the same journal
Scandinavian Journal of Gastroenterology
Gastroenterology and Hepatology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 35 hits
ReferencesLink to record
Permanent link

Direct link